57 12

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2019-11-19T06:02:59Z-
dc.date.available2019-11-19T06:02:59Z-
dc.date.issued2019-02-
dc.identifier.citationPHARMACEUTICS, v. 11, No. 2, Article no. 63en_US
dc.identifier.issn1999-4923-
dc.identifier.urihttps://www.mdpi.com/1999-4923/11/2/63-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/112333-
dc.description.abstractIn this study, a transferrin (T-f)-conjugated polymeric nanoparticle was developed for the targeted delivery of the chemotherapeutic agent doxorubicin (Dox) in order to overcome multi-drug resistance in cancer treatment. Our objective was to improve Dox delivery for producing significant antitumor efficacy in Dox-resistant (R) breast cancer cell lines with minimum toxicity to healthy cells. The results of our experiments revealed that Dox was successfully loaded inside a transferrin (T-f)-conjugated polymeric nanoparticle composed of poloxamer 407 (F127) and 123 (P123) (Dox/F127&P123-T-f), which produced nanosized particles (similar to 90 nm) with a low polydispersity index (similar to 0.23). The accelerated and controlled release profiles of Dox from the nanoparticles were characterized in acidic and physiological pH and Dox/F127&P123-T-f enhanced Dox cytotoxicity in OVCAR-3, MDA-MB-231, and MDA-MB-231(R) cell lines through induction of cellular apoptosis. Moreover, Dox/F127&P123-T-f inhibited cell migration and altered the cell cycle patterns of different cancer cells. In vivo study in MDA-MB-231(R) tumor-bearing mice demonstrated enhanced delivery of nanoparticles to the tumor site when coated in a targeting moiety. Therefore, Dox/F127&P123-T-f has been tailored, using the principles of nanotherapeutics, to overcome drug-resistant chemotherapy.en_US
dc.description.sponsorshipThis research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2018R1A2A2A05021143), and by the Medical Research Center Program (2018R1A5A2025272) through the NRF, funded by MSIP.en_US
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.subjectdoxorubicinen_US
dc.subjectdoxorubicin-resistant canceren_US
dc.subjectpolymeric nanoparticlesen_US
dc.subjecttransferrinen_US
dc.titleTransferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cellsen_US
dc.typeArticleen_US
dc.relation.no2-
dc.relation.volume11-
dc.identifier.doi10.3390/pharmaceutics11020063-
dc.relation.page63-80-
dc.relation.journalPHARMACEUTICS-
dc.contributor.googleauthorSoe, Zar Chi-
dc.contributor.googleauthorKwon, Jun Bum-
dc.contributor.googleauthorThapa, Raj Kumar-
dc.contributor.googleauthorOu, Wenquan-
dc.contributor.googleauthorNguyen, Hanh Thuy-
dc.contributor.googleauthorGautam, Milan-
dc.contributor.googleauthorOh, Kyung Taek-
dc.contributor.googleauthorChoi, Han-Gon-
dc.contributor.googleauthorKu, Sae Kwang-
dc.contributor.googleauthorYong, Chul Soon-
dc.contributor.googleauthorKim, Jong Oh-
dc.relation.code2019045021-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE